logo BDSP

Base documentaire


  1. Adjuvant therapy for stage III colon cancer : economics returns to research and cost-effectiveness of treatment.

    Article - En anglais

    Background

    In 1989, the National Cancer Institute issued a clinical announcement advising physicians of the benefits of combined levamisole and fluorouracil as an adjuvant treatment for patients with stage III colon cancer.

    Purpose

    We have estimated the cost-effectiveness of the combined treatment and estimated the social return on the National Institutes of Health (NIH) research investment that led to this innovative cancer treatment.

    Methods

    A computer simulation model, CAN*TROL, was used to estimate costs and benefits for a population cross-section receiving the adjuvant treatment.

    A method similar to « Q-TWiST » was used to assess the impact of quality-of-life adjustments.

    Mots-clés Pascal : Tumeur maligne, Côlon, Stade avancé, Fluorouracil, Fluor Composé organique, Base pyrimidique dérivé, Chimiothérapie, Lévamisole, Immunostimulant, Analyse coût efficacité, Economie santé, Simulation ordinateur, Qualité vie, Homme, Côlon pathologie, Intestin pathologie, Appareil digestif pathologie, Traitement, Informatique biomédicale, Stade III

    Mots-clés Pascal anglais : Malignant tumor, Colon, Advanced stage, Fluorine Organic compounds, Pyrimidine base derivatives, Chemotherapy, Immunostimulant agent, Cost efficiency analysis, Health economy, Computer simulation, Quality of life, Human, Colonic disease, Intestinal disease, Digestive diseases, Treatment, Biomedical data processing

    Logo du centre Notice produite par :
    Inist-CNRS - Institut de l'Information Scientifique et Technique

    Cote : 94-0447102

    Code Inist : 002B02R02. Création : 199406.